Dr Reddy's Labs PAT rises 33 percent to Rs 1482 crore in Q2

Published On 2023-10-28 08:00 GMT | Update On 2023-11-01 10:44 GMT

Hyderabad: Dr Reddy's Laboratories has reported a 33.02 per cent increase in consolidated profit after tax at Rs 1,482.2 crore in the second quarter ended September 30, led by the US generics market. The company had posted a consolidated profit after tax of Rs 1,114.2 crore in the same quarter a year ago, Dr Reddy's Laboratories Ltd (DRL) said in a regulatory filing.

The consolidated total revenue from operations was at Rs 6,902.6 crore, up 9 per cent, compared to Rs 6,331.8 crore in the year-ago period.

DRL's total expenses in the September quarter were up 11.14 per cent to Rs 5,305.1 crore.

Total income of DRL in the September quarter was at Rs 7,217.6 crore, up 13.25 per cent.

"We delivered another quarter of strong results with highest ever sales and profits, driven by market share gains & momentum in our US generics business and robust growth in Europe.

"We are continuing to strengthen our pipeline both organically and through business development to drive growth and create differentiation," Co-Chairman & MD, G V Prasad said.

DRL's global generics posted a revenue of Rs 6,113 crore in Q2, up 9.14 per cent from the year-ago quarter, driven by North America, emerging markets and Europe.

North America's revenue was at Rs 3,170 crore, a growth of 13 per cent, while that of Europe was at Rs 528.6 crore, with a growth of 26 per cent, the company said

While its revenue from 'Pharmaceutical Services and Active Ingredients' was at Rs 962.5 crore, up 16.95 per cent, as against Rs 823 crore, a year before.

Read also: Celevida Wellness: Dr Reddys launches Direct-to-consumer e-commerce website for diabetes nutrition

Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddys major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.

Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Dr Reddy's Labs PAT rises 33 percent to Rs 1482 crore in Q2

Similar News